⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262608 | 1.00 | — | — | |
| SCHEMBL4260874 | 1.00 | — | — | |
| SCHEMBL4267385 | 1.00 | — | — | |
| SCHEMBL4255434 | 1.00 | — | — | |
| SCHEMBL4254341 | 1.00 | — | — | |
| SCHEMBL4262094 | 1.00 | — | — | |
| SCHEMBL4269949 | 1.00 | — | — | |
| SCHEMBL4261336 | 1.00 | — | — | |
| SCHEMBL4261861 | 1.00 | — | — | |
| SCHEMBL3559505 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023182221-A1 | METHOD FOR PRODUCING QUANTUM DOTS | 日本化学工業株式会社 | 2023-09-28 | — | — | WO | disclosed |
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-7812026-B2 | Imidazole derivatives having a positive allosteric GABAB receptor modulator effect and methods of use | ASTRAZENECA AB (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7807658-B2 | Use of GabaB receptor agonists | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-7745474-B2 | tert-butyl 4-{[(4-chlorophenyl)carbonothioyl]amino}-2-(dimethylamino)-1-phenyl-1H-imidazole-5-carboxylate, having a positive allosteric GABA receptor modulator effect, used optionally in combination with a GABA receptor agonist; gastroesophageal reflux; irritable bowel syndrome; dyspepsia | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20090149474-A1 | GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090005428-A1 | Imidazole Derivatives for the Treatment of Gastrointestinal Disorders | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| WO-2002100869-A1 | NEW NAPSYLATE SALTS I | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100823-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100870-A1 | NEW NAPSYLATE SALTS II | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100871-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | disclosed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239843-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001041743-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |